以前に化学療法を受けたことのあるKRAS/NRASおよびBRAF野生型結腸直腸がんの参加者におけるアミバンタマブおよびFOLFIRIとセツキシマブ/ベバシズマブおよびFOLFIRIの比較研究 (OrigAMI-3)
以前に化学療法を受けたKRAS/NRASおよびBRAF野生型再発、切除不能または転移性結腸直腸がんの参加者を対象とした、アミバンタマブ+FOLFIRIとセツキシマブ/ベバシズマブ+FOLFIRIの無作為化非盲検第III相試験
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
Arizona
-
Chandler、Arizona、アメリカ、85224
- 募集
- Ironwood Cancer and Research Center
-
Gilbert、Arizona、アメリカ、85234
- 募集
- Banner MD Anderson Cancer Center
-
Prescott、Arizona、アメリカ、86301
- 完了
- Arizona Oncology Associates PC NAHOA
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- 募集
- St. Bernard's Medical Center
-
Springdale、Arkansas、アメリカ、72762
- 募集
- Highlands Oncology Group
-
-
California
-
Bakersfield、California、アメリカ、93309
- 募集
- CBCC Global Research
-
Glendale、California、アメリカ、91204
- 募集
- Los Angeles Cancer Network
-
Los Alamitos、California、アメリカ、90720
- 募集
- Cancer and Blood Specialty Clinic
-
Los Angeles、California、アメリカ、90033
- 募集
- USC Norris Comprehensive Cancer Center
-
Santa Monica、California、アメリカ、90404
- 募集
- UCLA
-
Santa Rosa、California、アメリカ、95403
- 募集
- Providence Medical Foundation
-
Torrance、California、アメリカ、90505
- 募集
- Torrance Memorial Physicians Network
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- University of Colorado Denver Anschultz Medical Campus
-
Denver、Colorado、アメリカ、80218
- 募集
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Norwich、Connecticut、アメリカ、06360
- 完了
- Eastern Connecticut Hematology & Oncology Assoc.
-
-
Florida
-
Fort Myers、Florida、アメリカ、33901
- 募集
- Florida Cancer Specialists South
-
Miami Beach、Florida、アメリカ、33140
- 完了
- Mount Sinai Medical Center Campus
-
Orlando、Florida、アメリカ、32804
- 募集
- AdventHealth Cancer Institute
-
St. Petersburg、Florida、アメリカ、33701-4553
- 募集
- Florida Cancer Specialists North Region
-
West Palm Beach、Florida、アメリカ、33401-3406
- 募集
- Florida Cancer Specialists East
-
-
Georgia
-
Athens、Georgia、アメリカ、30607
- 募集
- University Cancer And Blood Center LLC
-
Atlanta、Georgia、アメリカ、30303
- 募集
- Grady Memorial Hospital
-
Atlanta、Georgia、アメリカ、30318
- 募集
- Piedmont Cancer Institute
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Winship Cancer Institute Emory University
-
-
Illinois
-
Arlington Heights、Illinois、アメリカ、60005
- 募集
- Illinois Cancer Specialists
-
Peoria、Illinois、アメリカ、61615
- 募集
- Illinois CancerCare
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46237
- 募集
- Franciscan Health
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa Hospitals and Clinics
-
Waukee、Iowa、アメリカ、50263
- 募集
- Mission Cancer Blood
-
-
Kansas
-
Wichita、Kansas、アメリカ、67214
- 募集
- Cancer Center of Kansas
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70809
- 募集
- Mary Bird Perkins Cancer Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21237
- 募集
- MedStar Franklin Square Medical Center
-
Frederick、Maryland、アメリカ、21702
- 募集
- Frederick Health Hospital - James M Stockman Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Rogel Cancer Center
-
Detroit、Michigan、アメリカ、48202
- 募集
- Henry Ford Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- 募集
- Cancer And Hematology Centers of Western Michigan PC
-
-
Mississippi
-
Hattiesburg、Mississippi、アメリカ、39401
- 募集
- Hattiesburg Clinic
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School Of Medicine
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- 募集
- Nebraska Cancer Specialists
-
-
New Jersey
-
East Brunswick、New Jersey、アメリカ、08816
- 募集
- Astera Cancer Care
-
-
New York
-
Mineola、New York、アメリカ、11501
- 募集
- Perlmutter Cancer Center at NYU Long Island
-
New York、New York、アメリカ、10016
- 募集
- NYU Langone Medical Center NYU Hematology Associates
-
Shirley、New York、アメリカ、11967
- 募集
- New York Cancer and Blood Specialists
-
The Bronx、New York、アメリカ、10461
- 募集
- Montefiore Einstein Comprehensive Cancer Center
-
Williamsville、New York、アメリカ、14221
- 募集
- University of Buffalo Kaleida Health Cancer Care
-
-
Ohio
-
Canton、Ohio、アメリカ、44718
- 募集
- Gabrail Cancer Center
-
Cleveland、Ohio、アメリカ、44106
- 募集
- University Hospital of Cleveland
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- 募集
- Oregon Health And Science University
-
-
Pennsylvania
-
Penn Wynne、Pennsylvania、アメリカ、19096
- 募集
- Alliance Cancer Specialists at Main Line
-
Philadelphia、Pennsylvania、アメリカ、19111
- 募集
- Fox Chase Cancer Center
-
Philadelphia、Pennsylvania、アメリカ、19107
- 募集
- Thomas Jefferson University
-
Pittsburgh、Pennsylvania、アメリカ、15232 1301
- 募集
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37404
- 募集
- Tennessee Oncology Chattanooga
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University Medical Center
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Tennessee Oncology
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology Partners
-
-
Texas
-
Abilene、Texas、アメリカ、79606
- 募集
- Texas Oncology West Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- UT Southwestern Medical Center
-
Dallas、Texas、アメリカ、75235
- 募集
- Parkland Health and Hospital System
-
Dallas、Texas、アメリカ、75246
- 募集
- Texas Oncology DFW
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
Round Rock、Texas、アメリカ、77845
- 募集
- Baylor Scott & White Medical Center
-
San Antonio、Texas、アメリカ、78240
- 募集
- Texas Oncology - San Antonio
-
Temple、Texas、アメリカ、76508
- 募集
- Scott And White Memorial Hospital
-
Tyler、Texas、アメリカ、75701
- 募集
- UT Health East Texas HOPE Cancer Center
-
-
Virginia
-
Arlington、Virginia、アメリカ、22201
- 募集
- Virginia Cancer Specialists
-
Richmond、Virginia、アメリカ、23249
- 募集
- Richmond VA Medical Center
-
Richmond、Virginia、アメリカ、23298
- 募集
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Lacey、Washington、アメリカ、98503
- 募集
- Providence Regional Cancer System
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- Medical College Of Wisconsin
-
-
-
-
-
Birmingham、イギリス、B9 5ST
- 募集
- Birmingham Heartlands Hospital
-
Hull、イギリス、HU16 5JQ
- 募集
- Castle Hill Hospital
-
Leeds、イギリス、LS9 7TF
- 募集
- St James University Hospital
-
London、イギリス、EC1A 7BE
- 募集
- St Bartholomew's Hospital
-
London、イギリス、SW3 6JJ
- 募集
- Royal Marsden Hospital
-
London、イギリス、NW1 2BU
- 募集
- University College Hospital
-
Northwood、イギリス、HA6 2RN
- 募集
- Mount Vernon Cancer Centre
-
-
-
-
-
Beer Yaakov、イスラエル、70300
- 募集
- Yitzhak Shamir Medical Center
-
Haifa、イスラエル、3109601
- 募集
- Rambam Medical Center
-
Jerusalem、イスラエル、9112001
- 募集
- Hadassah Medical Center
-
Petah Tikva、イスラエル、4941492
- 募集
- Rabin Medical Center
-
Ramat Gan、イスラエル、52621
- 募集
- Sheba Medical Center
-
Tel Aviv、イスラエル、6423906
- 募集
- Tel Aviv Sourasky Medical Center
-
Tel Aviv、イスラエル、69710
- 募集
- Assuta MC
-
-
-
-
-
Catania、イタリア、95122
- 募集
- ARNAS Garibaldi P O Nesima
-
Florence、イタリア、50134
- 募集
- Careggi University Hospital
-
Milan、イタリア、20133
- 募集
- Istituto Dei Tumori Di Milano
-
Novara、イタリア、28100
- 募集
- Fondazione del Piemonte per I Oncologia IRCC Candiolo
-
Padova、イタリア、35128
- 募集
- Istituto Oncologico Veneto - IRCCS
-
Pisa、イタリア、56126
- 募集
- Azienda Ospedaliero Universitaria Pisana
-
Rozzano、イタリア、20089
- 募集
- Istituto Clinico Humanitas
-
Udine、イタリア、33100
- 完了
- Azienda Sanitaria Universitaria Friuli Centrale ASU FC
-
-
-
-
-
Delhi、インド、110085
- 募集
- Rajiv Gandhi Cancer Institute and Research Centre
-
Hyderabad、インド、500032
- 募集
- Asian Institute Of Gastroenterology
-
Kolkata、インド、700053
- 募集
- B P Poddar Hospital and Medical research Limited
-
Mumbai、インド、400012
- 募集
- Tata Memorial Hospital
-
New Delhi、インド、110029
- 募集
- Safdarjung Hospital
-
Pune、インド、411004
- 募集
- Deenanath Mangeshkar Hospital and Research Centre
-
Varanasi、インド、221005
- 募集
- Mahamana Pandit Madan Mohan Malviya Cancer Centre
-
Vellore、インド、632004
- 募集
- Christian medical
-
-
-
-
-
Amersfoort、オランダ、3813 TZ
- 募集
- Meander Medisch Centrum
-
Amsterdam、オランダ、1066 CX
- 募集
- Antoni van Leeuwenhoek
-
Nijmegen、オランダ、6525 GA
- 募集
- Radboud University Medical Center
-
Rotterdam、オランダ、3015 GD
- 募集
- Erasmus MC
-
Tilburg、オランダ、5042 AD
- 募集
- ETZ TweeSteden
-
-
-
-
-
Concord、オーストラリア、2139
- 完了
- Concord Hospital
-
Heidelberg、オーストラリア、3084
- 募集
- Warringal Private Hospital
-
South Woodville、オーストラリア、5011
- 募集
- Queen Elizabeth Hospital
-
St Albans、オーストラリア、3021
- 募集
- Western Health Sunshine Hospital
-
-
-
-
-
Gothenburg、スウェーデン、413 45
- 完了
- Sahlgrenska Universitetssjukhuset
-
Lund、スウェーデン、222 42
- 募集
- Skanes universitetssjukhus
-
Stockholm、スウェーデン、171 76
- 募集
- Karolinska Universitetssjukhuset
-
Stockholm、スウェーデン、118 83
- 募集
- Sodersjukhuset
-
Uppsala、スウェーデン、SE 751 85
- 募集
- Uppsala University
-
-
-
-
-
Badajoz、スペイン、06006
- 募集
- Hosp. Univ. de Badajoz
-
Barcelona、スペイン、08028
- 募集
- Hosp. Univ. Quiron Dexeus
-
Barcelona、スペイン、08003
- 募集
- Hosp. Del Mar
-
Barcelona、スペイン、08041
- 募集
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、スペイン、08035
- 募集
- Hosp Univ Vall D Hebron
-
Madrid、スペイン、28034
- 募集
- Hosp. Univ. Ramon Y Cajal
-
Madrid、スペイン、28041
- 募集
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28007
- 募集
- Hosp. Gral. Univ. Gregorio Maranon
-
Madrid、スペイン、28040
- 募集
- Hosp Univ Fund Jimenez Diaz
-
Madrid、スペイン、28002
- 募集
- Hosp San Francisco de Asis
-
Málaga、スペイン、29010
- 募集
- Hosp Regional Univ de Malaga
-
Pamplona、スペイン、31008
- 募集
- Clinica Univ. de Navarra
-
Seville、スペイン、41013
- 募集
- Hosp. Virgen Del Rocio
-
Valencia、スペイン、46010
- 募集
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Bangkok、タイ、10700
- 募集
- Siriraj Hospital
-
Bangkok、タイ、10400
- 募集
- Ramathibodi Hospital
-
Chiang Mai、タイ、50200
- 募集
- Chiang Mai University
-
Songkhla、タイ、90110
- 募集
- Songklanagarind hospital
-
-
-
-
-
Adana、トルコ(Türkiye)、01060
- 募集
- Adana City Hospital
-
Ankara、トルコ(Türkiye)、06800
- 募集
- Ankara Bilkent Sehir Hastanesi
-
Ankara、トルコ(Türkiye)、06010
- 募集
- Gulhane Egitim ve Arastirma Hastanesi
-
Ankara、トルコ(Türkiye)、06200
- 募集
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara、トルコ(Türkiye)、06560
- 募集
- Gazi Universitesi Hastanesi
-
Antalya、トルコ(Türkiye)、07025
- 募集
- Memorial Antalya Hospital
-
Edirne、トルコ(Türkiye)、22030
- 募集
- Trakya University Medical Faculty
-
Istanbul、トルコ(Türkiye)、34147
- 募集
- Bakirkoy Training and Research Hospital
-
Istanbul、トルコ(Türkiye)、34899
- 募集
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi
-
Konya、トルコ(Türkiye)、42090
- 募集
- Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi
-
Sakarya、トルコ(Türkiye)、54290
- 募集
- Sakarya University Training and Research Hospital
-
-
-
-
-
Berlin、ドイツ、13353
- 募集
- Charite Universitatsmedizin Berlin Campus Virchow Klinikum
-
Frankfurt am Main、ドイツ、60488
- 募集
- Krankenhaus NorthWest
-
Heidelberg、ドイツ、69120
- 募集
- National Center for Tumor Diseases NCT
-
Mainz、ドイツ、55131
- 募集
- Universitatsmedizin der Johannes Gutenberg Universitat Mainz
-
Munich、ドイツ、81377
- 募集
- Klinikum der Universitaet Muenchen
-
-
-
-
-
Eger、ハンガリー、3300
- 完了
- Markhot Ferenc Oktatokorhaz es Rendelointezet
-
Pécs、ハンガリー、7624
- 完了
- Pecsi Tudomanyegyetem
-
Szeged、ハンガリー、6720
- 完了
- Szegedi Tudomanyegyetem
-
-
-
-
-
Avignon、フランス、84918
- 募集
- Institut Sainte Catherine
-
Pessac、フランス、33604
- 募集
- Hopital Haut Leveque
-
Poitiers、フランス、86000
- 募集
- CHU De Poitiers
-
-
-
-
-
Barretos、ブラジル、14780 070
- 募集
- Fundacao Pio XII
-
Caxias do Sul、ブラジル、95070 560
- 募集
- Fundacao Universidade de Caxias do Sul
-
Jaú、ブラジル、17210 080
- 募集
- Fundacao Doutor Amaral Carvalho
-
Porto Alegre、ブラジル、91350 200
- 募集
- Hospital Nossa Senhora da Conceicao S A
-
Salvador、ブラジル、40050 410
- 募集
- Hospital Santa Izabel Santa Casa de Misericordia da Bahia
-
São José do Rio Preto、ブラジル、15090-000
- 募集
- Funfarme Sjrp
-
São Paulo、ブラジル、01246 000
- 募集
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo、ブラジル、01509 900
- 募集
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、05651 900
- 募集
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
Vitória、ブラジル、29043 260
- 募集
- Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
-
-
-
-
-
San Juan、プエルトリコ、00935
- 募集
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Anderlecht、ベルギー、1070
- 募集
- Institut Jules Bordet
-
Edegem、ベルギー、2650
- 募集
- UZ Antwerpen
-
Ghent、ベルギー、9000
- 完了
- AZ Maria Middelares
-
Haine Saint Paul La Louviere、ベルギー、7100
- 募集
- Jolimont
-
Kortrijk、ベルギー、8500
- 募集
- Az Groeninge
-
Leuven、ベルギー、3000
- 募集
- Universitair Ziekenhuis Leuven
-
Liège、ベルギー、4000
- 募集
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
-
-
-
-
Bialystok、ポーランド、15 027
- 完了
- Bialostockie Centrum Onkologii im Marii Sklodowskiej Curie w Bialymstoku
-
Biała Podlaska、ポーランド、21 500
- 完了
- Wojewodzki Szpital Specjalistyczny
-
Brzozów、ポーランド、36 200
- 募集
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
-
Gdansk、ポーランド、80 214
- 募集
- Uniwersyteckie Centrum Kliniczne
-
Gliwice、ポーランド、44 100
- 完了
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach
-
Lodz、ポーランド、93 339
- 募集
- Instytut Centrum Zdrowia Matki Polki
-
Olsztyn、ポーランド、10 228
- 完了
- Szpital Kliniczny MSWiA z WMCO
-
Opole、ポーランド、45 061
- 募集
- SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego
-
Warsaw、ポーランド、02 034
- 募集
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
-
George Town、マレーシア、10450
- 募集
- Hospital Pulau Pinang
-
Ipoh、マレーシア、30450
- 募集
- Hospital Raja Permaisuri Bainun
-
Kuala Lumpur、マレーシア、59100
- 募集
- University Malaya Medical Centre
-
Kuala Lumpur、マレーシア、50586
- 募集
- Hospital Kuala Lumpur
-
Kuching、マレーシア、93586
- 募集
- Hospital Umum Sarawak
-
Putrajaya、マレーシア、62250
- 募集
- Institut Kanser Negara Clinical Research Center
-
-
-
-
-
Chihuahua City、メキシコ、31217
- 募集
- Centro Oncologico de Chihuahua
-
Guadalajara、メキシコ、44680
- 募集
- Actualidad Basada En La Investigacion Del Cancer
-
Mexico City、メキシコ、14080
- 募集
- Instituto Nacional de Cancerologia
-
Mexico City、メキシコ、06760
- 募集
- Centro Oncologico Personalizado Cope S De R L De C V
-
Monterrey、メキシコ、64460
- 募集
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Puebla City、メキシコ、72530
- 募集
- Oncocenter
-
Querétaro、メキシコ、76000
- 募集
- Cuidados Oncologicos
-
Querétaro、メキシコ、76230
- 募集
- Health Pharma Queretaro SA de CV
-
Tijuana、メキシコ、22010
- 募集
- COI Centro Oncologico Internacional Tijuana
-
-
-
-
-
Brasov、ルーマニア、500091
- 募集
- Centrul Medical Unirea SRL
-
Bucharest、ルーマニア、013812
- 募集
- Spitalul Memorial Baneasa
-
Bucharest、ルーマニア、014142
- 完了
- Ponderas Academic Hospital
-
Bucharest、ルーマニア、077190
- 完了
- Neolife Medical Center Bucharest
-
Cluj-Napoca、ルーマニア、400015
- 募集
- Institutul Oncologic 'Prof Dr. Ion Chiricuta' Cluj-Napoca
-
Craiova、ルーマニア、200542
- 募集
- Clinica de Oncologie Sf Nectarie
-
Iași、ルーマニア、700483
- 募集
- Institutul Regional de Oncologie Iasi
-
Oradea、ルーマニア、410469
- 募集
- Pelican Impex SRL
-
-
-
-
-
Beijing、中国、100142
- 募集
- Beijing Cancer Hospital
-
Beijing、中国、100034
- 募集
- Peking University First Hospital
-
Beijing、中国、100050
- 募集
- Beijing Friendship Hospital Capital Medical University
-
Changchun、中国、130021
- 募集
- The First Bethune Hospital of Jilin University
-
Changsha、中国、410013
- 募集
- Hunan Cancer hospital
-
Chengdu、中国、610041
- 募集
- West China Hospital of Sichuan University
-
Ganzhou、中国、341000
- 募集
- Ganzhou Cancer Hospital
-
Guangzhou、中国、510655
- 募集
- The Sixth Affiliated Hospital Sun Yat sen University
-
Guangzhou、中国、519041
- 募集
- Guangdong Provincial People's Hospital
-
Guangzhou、中国、100142
- 募集
- Sun Yat Sen University Cancer Center
-
Hangzhou、中国、310022
- 募集
- Zhejiang Cancer Hospital
-
Hangzhou、中国、310009
- 募集
- The Second Affiliated Hospital of Zhejiang University
-
Harbin、中国、150081
- 募集
- Harbin medical university cancer hospital
-
Huizhou、中国、516001
- 募集
- Huizhou Central People's Hospital
-
Lanzhou、中国、730050
- 募集
- Gansu Provincial Cancer Hospital
-
Nanchang、中国、330006
- 募集
- The First Affiliated Hospital of NanChang University
-
Shanghai、中国、200032
- 募集
- Fudan University Shanghai Cancer Center
-
Shenyang、中国、110042
- 募集
- Liaoning Cancer Hospital and Institute
-
Tianjin、中国、300060
- 募集
- Tianjin Medical University Cancer Institute and Hospital
-
Wuhan、中国、430079
- 募集
- Hubei Cancer Hospital
-
-
-
-
-
Kaohsiung City、台湾、833
- 募集
- Chang Gung Memorial Hospital
-
Kaohsiung City、台湾、80756
- 募集
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung、台湾、40705
- 募集
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- 募集
- National Cheng Kung University Hospital
-
Taipei、台湾、112
- 募集
- Taipei Veterans General Hospital
-
Taipei、台湾、10043
- 募集
- National Taiwan University Hospital
-
Taoyuan、台湾、333
- 募集
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Chiba、日本、260 0801
- 募集
- Chiba Cancer Center
-
Chūōku、日本、104 0045
- 募集
- National Cancer Center Hospital
-
Kashiwa、日本、277 8577
- 募集
- National Cancer Center Hospital East
-
Nagoya、日本、464-8681
- 募集
- Aichi Cancer Center
-
Osaka、日本、541 8567
- 募集
- Osaka International Cancer Institute
-
Osaka、日本、540 0006
- 募集
- National Hospital Organization Osaka National Hospital
-
Sakai、日本、590 0197
- 募集
- Kindai University Hospital
-
Shizuoka、日本、411 8777
- 募集
- Shizuoka Cancer Center
-
Suita、日本、565 0871
- 募集
- The University of Osaka Hospital
-
Tokyo、日本、135 8550
- 募集
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
Daegu、韓国、41404
- 募集
- Kyungpook National University Chilgok Hospital
-
Seoul、韓国、05505
- 募集
- Asan Medical Center
-
Seoul、韓国、03080
- 募集
- Seoul National University Hospital
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center
-
Seoul、韓国、02841
- 募集
- Korea University Anam Hospital
-
Seoul、韓国、03722
- 募集
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、06591
- 募集
- The Catholic University of Korea Seoul St Mary s Hospital
-
-
-
-
-
Hong Kong、香港
- 募集
- Queen Mary Hospital
-
Shatin、香港
- 募集
- Prince Of Wales Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Have histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Participants must have recurrent, unresectable or metastatic disease
- Determined to have kirsten rat sarcoma viral oncogene/neuroblastoma RAS viral oncogene homolog (KRAS/NRAS), G12, G13 and v-raf murine sarcoma viral oncogene homolog B (BRAF) V600X (X represents any single amino acid change from the original amino acid) wild type status by local and/or central next-generation sequencing (NGS) testing
- Must agree to the submission of fresh or archival tumor tissue post progression from the most recent therapy, if clinically feasible
- Have measurable disease according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1
- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1
- Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy. Participants can receive anti-VEGF as prior line of therapy
Exclusion Criteria:
- Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
- Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI
- Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
- Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor
- Has prior exposure to irinotecan, any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: Amivantamab + FOLFIRI
Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium [folinic acid] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. |
Amivantamab will be administered.
他の名前:
5-fluorouracil will be administered as chemotherapy regimen. Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
他の名前:
Irinotecan will be administered as chemotherapy regimen. |
|
アクティブコンパレータ:Arm B: Cetuximab or Bevacizumab + FOLFIRI
Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. |
5-fluorouracil will be administered as chemotherapy regimen. Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
他の名前:
Cetuximab will be administered.
他の名前:
Irinotecan will be administered as chemotherapy regimen. Bevacizumab will be administered.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
時間枠:Up to 2 years 1 month
|
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v)1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date. |
Up to 2 years 1 month
|
|
Overall Survival (OS)
時間枠:Up to 4 years 4 months
|
OS is defined as the time from the date of randomization to the date of participant's death due to any cause. |
Up to 4 years 4 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR) as Assessed by BICR
時間枠:Up to 4 years 4 months
|
ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by BICR using RECIST v1.1 criteria. |
Up to 4 years 4 months
|
|
ORR as Assessed by Investigator
時間枠:Up to 4 years 4 months
|
ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by investigator using RECIST v1.1 criteria. |
Up to 4 years 4 months
|
|
Progression Free Survival as Assessed by Investigator
時間枠:Up to 4 years 4 months
|
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by investigator. |
Up to 4 years 4 months
|
|
Duration of Response (DoR) as Assessed by BICR
時間枠:Up to 4 years 4 months
|
DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by BICR. |
Up to 4 years 4 months
|
|
Duration of Response as Assessed by Investigator
時間枠:Up to 4 years 4 months
|
DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by investigator. |
Up to 4 years 4 months
|
|
Time to Response (TTR) as Assessed by BICR
時間枠:Up to 4 years 4 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by BICR. |
Up to 4 years 4 months
|
|
TTR as Assessed by Investigator
時間枠:Up to 4 years 4 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by investigator. |
Up to 4 years 4 months
|
|
Progression Free Survival After Subsequent Therapy (PFS2)
時間枠:Up to 4 years 4 months
|
PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent systemic anticancer therapy, based on investigator assessment or death, whichever comes first. |
Up to 4 years 4 months
|
|
Disease Control Rate (DCR) as Assessed by BICR
時間枠:Up to 4 years 4 months
|
DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as defined by BICR using RECIST v1.1. |
Up to 4 years 4 months
|
|
Disease Control Rate as Assessed by Investigator
時間枠:Up to 4 years 4 months
|
DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as assessed by investigator. |
Up to 4 years 4 months
|
|
Time to Treatment Failure
時間枠:Up to 4 years 4 months
|
Time to treatment failure is defined as time from randomization to discontinuation of therapy for any reason including death, progression, toxicity, or initiation of new anticancer therapy. |
Up to 4 years 4 months
|
|
Curative Resection (R0) Rate
時間枠:Up to 4 years 4 months
|
Curative resection (R0) rate is defined as the percentage of randomized participants who underwent curative-intent surgery where the residual tumor classification was R0. |
Up to 4 years 4 months
|
|
Number of Participants with Adverse Events (AEs) by Severity
時間枠:Up to 4 years 4 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to 4 years 4 months
|
|
Number of Participants with Abnormalities in Laboratory Values
時間枠:Up to 4 years 4 months
|
Participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported. |
Up to 4 years 4 months
|
|
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
時間枠:From baseline up to 4 years 4 months
|
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
From baseline up to 4 years 4 months
|
|
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C30
時間枠:Up to 4 years 4 months
|
Time to worsening in symptoms and functioning as measured by EORTC QLQ-C30 score will be reported. The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
Up to 4 years 4 months
|
|
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29) Score
時間枠:From baseline up to 4 years 4 months
|
The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ-CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms. |
From baseline up to 4 years 4 months
|
|
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-CR29 Score
時間枠:Up to 4 years 4 months
|
Time to worsening in symptoms and functioning as measured by EORTC QLQ-CR29 will be reported. EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ-CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms. Change from baseline in the EORTC QLQ-CR29 score will be reported. |
Up to 4 years 4 months
|
|
Overall Side Effect Burden as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Item 168 Scale Score
時間枠:Up to 4 years 4 months
|
EORTC item 168 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much. Higher scores indicates severe symptoms. |
Up to 4 years 4 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 腸の病気
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 腸の腫瘍
- 直腸疾患
- 結腸疾患
- 結腸直腸腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カムプトテシン
- アルカロイド
- 酵素と補酵素
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- ピリミジン
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- ウラシル
- ピリミジノン
- コエンザイム
- ベバシズマブ
- イリノテカン
- セツキシマブ
- フルオロウラシル
- ロイコボリン
- レボルイコボリン
- アミバンタマブ
その他の研究ID番号
- 61186372COR3002
- 2024-513853-66-00 (レジストリ識別子:EUCT number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。